Reinvigorated Antibiotics Pipeline Could Produce Four NMEs In 2014
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With two novel antibiotics approved and two more under review, 2014 is seeing the end of a long lean period for antibacterial R&D, helped by incentives like Qualified Infectious Disease Product designation. But only one candidate, Cubist’s ceftozolane/tazobactam, addresses the urgent need to target resistant Gram-negative bacteria.